The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria.
about
Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).DNA methylation of hMLH1 correlates with the clinical response to cisplatin after a surgical resection in Non-small cell lung cancerBioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.Melittin induces NSCLC apoptosis via inhibition of miR-183
P2860
The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
The changing landscape of phas ...... biomarker selection criteria.
@en
The changing landscape of phas ...... biomarker selection criteria.
@nl
type
label
The changing landscape of phas ...... biomarker selection criteria.
@en
The changing landscape of phas ...... biomarker selection criteria.
@nl
prefLabel
The changing landscape of phas ...... biomarker selection criteria.
@en
The changing landscape of phas ...... biomarker selection criteria.
@nl
P2093
P2860
P921
P356
P1433
P1476
The changing landscape of phas ...... biomarker selection criteria.
@en
P2093
Alfred W Rademaker
Jyoti D Patel
Melissa L Johnson
Ryan D Gentzler
Sarah E Yentz
P2860
P304
P356
10.1002/CNCR.28956
P407
P577
2014-08-25T00:00:00Z